Compass Therapeutics, Inc.
CMPXHealthcare|Biotechnology|US
$0.76
+0.07 (+10.84%)
DCF Value
$0.12
Tangible Book / Share
$0.89
Cash / Share
$0.96
Clinical Trials (29)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05506943 A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | Biliary Tract Cancer, Cholangiocarcinoma | P2P3 | Active | 168 | RCT, Single-blind | CTX-009, Paclitaxel |
| NCT05711940 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | Treatment Resistant Depression | P3 | Active | 572 | RCT, Double-blind | Psilocybin |
| NCT07570654 Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | PTSD - Post Traumatic Stress Disorder, PTSD | P2P3 | Recruiting | 300 | RCT, Double-blind | COMP360 psilocybin |
| NCT06247839 The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | Major Depressive Disorder | P3 | Recruiting | 20 | Open-label | Psilocybin |
| NCT06548412 CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers | Metastatic Biliary Tract Cancer | P1P2 | Recruiting | 50 | RCT, Open-label | Gemcitabine, Cisplatin, Durvalumab, CTX-009 |
| NCT07392957 Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma | Glioblastoma | P1P2 | Recruiting | 54 | RCT, Open-label | CTX-009, CTX-471 |
| NCT05733546 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | Major Depressive Disorder | P2 | Active | 102 | RCT, Double-blind | Psilocybin |
| NCT06150664 A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Non Small Cell Lung Cancer, Triple Negative Breast Cancer | P1 | Recruiting | 85 | Open-label | CTX-8371 |
| NCT07419841 A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC) | P1 | Recruiting | 70 | Open-label | CTX-10726 |
| NCT05624268 Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Treatment Resistant Depression | P3 | Completed | 258 | RCT, Double-blind | Psilocybin |
| NCT04492033 A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer | P1P2 | Terminated | 41 | Open-label | CTX-009 (ABL001), Paclitaxel, Irinotecan |
| NCT07662031 Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer | Colorectal Cancer, Metastatic Colorectal Cancer | P2 | Not Yet Recruiting | 25 | Open-label | Tovecimig, Irinotecan, Leucovorin, 5-Fluorouracil (5-FU) |
| NCT07684170 Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | P2 | Not Yet Recruiting | 58 | RCT, Open-label | CTX-471 |
| NCT05312151 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Post Traumatic Stress Disorder | P2 | Completed | 22 | Open-label | Psilocybin |
| NCT05481736 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | Anorexia Nervosa | P2 | Completed | 32 | RCT, Double-blind | Psilocybin |
| NCT03775200 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | Treatment Resistant Depression | P2 | Completed | 233 | RCT, Double-blind | Psilocybin |
| NCT04656301 Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | Body Dysmorphic Disorders | P2 | Completed | 12 | Open-label | Psilocybin |
| NCT05220410 The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | Treatment Resistant Depression, Suicidal Ideation | P2 | Completed | 20 | Open-label | Psilocybin |
| NCT05381974 The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD | Treatment-Resistant Major Depressive Disorder | P2 | Withdrawn | — | Open-label | Psilocybin |
| NCT04739865 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | Treatment Resistant Depression | P2 | Completed | 19 | Open-label | Psilocybin |
| NCT04433845 The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | Treatment Resistant Depression | P2 | Unknown | 15 | Open-label | Psilocybin |
| NCT04661514 Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | Anorexia Nervosa | P2 | Completed | 16 | Open-label | Psilocybin |
| NCT04433858 An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) | Treatment Resistant Depression | P2 | Unknown | 27 | Open-label | Psilocybin |
| NCT05513742 A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer, Colon Cancer | P2 | Completed | 49 | Open-label | CTX-009 |
| NCT03881488 Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | Locally Advanced Solid Tumor, Metastatic Cancer | P1 | Terminated | 100 | Open-label | CTX-471, Pembrolizumab (KEYTRUDA®) |
| NCT07256496 Enhanced Dialectical Behavior Therapy for Adolescents | Suicidality | N/A | Completed | 47 | Open-label | — |
| NCT02514590 Wireless Spinal Cord Stimulation for Chronic Pain | Back Pain | N/A | Completed | 49 | Open-label | — |
| NCT04203992 Videogame for the Prevention of Doping and Supplement Abuse in Teenage Athletes | Doping in Sport, Performance Enhancing Product Use | N/A | Unknown | 284 | Open-label | — |
| NCT04519957 Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | Treatment Resistant Depression | Completed | 66 | — | — |